NCT04355520 2020-04-21A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerChia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 1/2 Unknown42 enrolled